Regenera set to begin Singapore trials
Tuesday, 03 August, 2004
Regenera (ASX: RGA) has received ethics committee approval to begin Phase III human clinical trials for its synthetic steroid drug Visagen at the Singapore Eye Research Institute.
The initial trial will test the treatment on cystoid macular oedema, and the company plans to expand the study with trials evaluating the therapy in age related macular degeneration, uveitis, diabetic macular oedema and as a co-treatment with photodynamic therapy.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
